Medtronic plc (MDT)

FairStock Score: 51/100 — MIXED

Key Financials

Strengths

• Dominant position in cardiovascular and neurosurgical devices with high switching costs and clinical moat
• Reliable free cash flow generation of $4.1B annually supporting dividends and buybacks
• Low beta of 0.73 provides defensive characteristics during market downturns
• Recurring revenue model from installed base of implantable devices reduces earnings volatility
• Q1 2026 net margin of 12.68% demonstrates operational profitability

Concerns

• Valuation is severely detached from intrinsic value with EV/EBITDA of 61.78 and negative margin of safety of -230%
• Deteriorating financial quality evidenced by Piotroski F-Score of 6/9 and elevated leverage relative to returns
• Weak capital efficiency with ROE of 9.39% and ROCE of 4.57% suggests past acquisition integration challenges
• Absence of visible revenue growth despite being mature, well-positioned market leader raises organic growth concerns

AI Analysis

Medtronic presents a classic conundrum: a quality business trading at a decidedly un-quality price. Let me be direct—at $91.34 with a Graham Number of $27.65, we're looking at a margin of safety of negative 230%. This is not a margin of safety; it's a margin of peril. The company operates in an excellent industry with recurring revenue from implantable devices, a genuine competitive moat built on clinical evidence and switching costs. The balance sheet shows reasonable leverage at 0.57 D/E, and the business generates solid free cash flow of $4.1B annually. However, the financial metrics trouble me deeply. An EV/EBITDA of 61.78 is extraordinarily expensive—we're paying $61.78 for every dollar of operating earnings. The ROE of 9.39% and ROCE of 4.57% are frankly mediocre for a $117B company. This suggests capital allocation has been suboptimal, likely through dilutive acquisitions. The Piotroski F-Score of 6/9 indicates deteriorating financial health, while the Altman Z-Score of 2.51 sits in the gray zone of financial distress. Most critically, we see no revenue growth data and the FCF yield of merely 2% tells me the stock price has inflated far beyond intrinsic value. Medtronic is a fine business, but at this valuation, it's a poor investment. I require a margin of safety, not a margin of fantasy.

Bull Case

Medtronic's diversified portfolio and essential role in healthcare delivery provide downside protection; successful integration of recent acquisitions and innovations in remote monitoring could reignite organic growth. The dividend remains well-covered by FCF, offering income investors a defensive healthcare holding with modest appreciation potential.

Bear Case

The astronomical valuation multiples leave no room for disappointment; deteriorating financial scores suggest operational headwinds ahead. A market correction or recession could expose the company's weak returns on capital, driving a significant multiple compression that would devastate shareholders.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer